The purpose of this Business Case for investment in TB research and development is to demonstrate that a viable global market exists for new TB vaccines and to initiate discussions among various key stakeholders, including donors, pharmaceutical companies, vaccine developers, the WHO, and representatives from high disease burden countries, and civil society. This is an effort to ensure adequate finance and risk-sharing among the public and private sectors, and to advocate for the portfolio management approach as the most efficient and effective mechanism for facilitating the development of new TB vaccines.
Anon. TB Vaccine Research and Development: A Business Case for Investment. (2013) 64 pp.